Business Wire

Fujirebio Confirms Its Engagement in Blood-based Alzheimer’s Disease Biomarker Testing with the Launch of the Fully Automated Lumipulse® G β-Amyloid 1-42 and β-Amyloid 1-40 Plasma Assays for Research Use Only

Share

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G β-Amyloid 1-42 Plasma and Lumipulse G β-Amyloid 1-40 Plasma assays for the fully automated LUMIPULSE G immunoassay systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of β-amyloid1-42 and β-amyloid1-40 in human plasma within just 35 minutes.

“With the launch of these two new tests on our robust LUMIPULSE G platform, Fujirebio truly becomes an essential actor in the field of blood-based testing,” said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “Our cerebrospinal fluid-based neurodegeneration IVD tests are already used by laboratories for routine testing in many countries across the world for decades, and this release continues the new chapter that we started writing earlier this month, with the launch of the Lumipulse G pTau 181 Plasma.”

The two new automated blood-based biomarker assays are available for Research Use Only. They will allow researchers and clinical research professionals across the world to further study the clinical utility of the Aβ1-42, Aβ1-40 and the pTau 181 markers in Alzheimer’s disease and related disorders on the LUMIPULSE G platform. This platform has the required throughput and meets the regulatory requirements to support possible future routine use of blood-based testing of these markers.

The Lumipulse G β-Amyloid 1-42 Plasma and the Lumipulse G β-Amyloid 1-40 Plasma assays, together with the already available Lumipulse G pTau 181 Plasma assay, complement the panel of four key cerebrospinal fluid (CSF) assays (Aβ1-42, Aβ1-40, tTau and pTau 181) already available within the Lumipulse G as well as the INNOTEST® Neuro product portfolio. These four CSF parameters can provide essential information on the presence of amyloid and tau pathology in neurodegenerative disease.

There is hope that blood-based testing can become an even simpler, more accessible, and more scalable approach to help support the diagnosis of Alzheimer’s disease. Current research indicates that the plasma β-amyloid1-42/β-amyloid1-40 ratio has the potential to be used in clinical settings and within clinical trials to predict brain β-amyloid burden.1-2 It could also be used as a tool to evaluate target engagement and efficacy of disease-modifying drugs.3

The development of the Lumipulse G β-Amyloid 1-42 Plasma and Lumipulse G β-Amyloid 1-40 Plasma assays has been supported by the Flanders Innovation & Entrepreneurship (VLAIO).

About Fujirebio

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.

Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. More information can be found at www.fujirebio.com/alzheimer.

References:

1. Palmqvist S, et al. EMBO Mol Med, 11(12): e11170, 2019.
2. Nakamura A, et al. Nature, 554(7691): 249-254, 2018.
3. Teunissen C, et al. Lancet Neurol, 21(1): 66-77, 2022.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media:
Christiaan De Wilde
CEO Fujirebio Europe
Phone: +32 9329 1703

Public Relations Section, Public Relations/Sustainability Dept.
Phone: +81-3-6279-0884 
E-mail: pr@hugp.com

For investors and analysts:
IR/SR Dept.
Phone: +81-3-5909-3337
E-mail:ir@hugp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lumenis OptiLight Wins 2022 MedTech Breakthrough Award: Best New Technology Solution for Ophthalmology25.5.2022 16:23:00 EEST | Press release

Lumenis Be., a leading energy-based medical device company for aesthetic and eye care applications, today announced that OptiLight has received the highly competitive MedTech Breakthrough Award for “Best New Technology Solution for Ophthalmology.” This year, MedTech’s range of health and medical technology categories attracted more than 3,900 nominations from over 15 countries, from which MedTech selected OptiLight for this prestigious recognition. The win follows Lumenis’ MedTech awards for Best Overall Medical Device Company in 2021 and Best New Surgical Technology Solution in 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005607/en/ (Graphic: Business Wire) OptiLight is a groundbreaking, light-based treatment. It is the first and only light treatment FDA approved for management of dry eye disease, a very common condition that causes dry, gritty eyes and fluctuating vision for an estimated 49 million Americans.

Everest Technologies Recognized by Manhattan Associates for Commerce Services25.5.2022 16:00:00 EEST | Press release

Everest Technologies today announced that it has been named as the winner of the Commerce Services Partner of the Year award by Manhattan Associates. The awards were presented at Momentum 2022, Manhattan Associates’ annual event, held on May 23-25 in Florida. At Momentum 2022, the partners were recognized for their exceptional work in providing top-quality solutions and services that address complex business challenges and continuously drive success, value and return on investment for the customers. Commenting on the award win, Eric Lamphier, Senior Director of Alliances, said, “Manhattan Associates is committed to developing, supporting, and recognizing innovations that build a smooth supply chain and improve the end consumer experience. We are conscious of the value add of our robust partner network and are proud of the innovative and efficient solutions developed by them to make our customers continue seamlessly on their business journey.” “We are very passionate and deliberate abou

Upflex Announces $30M Series A From Top Strategic & Venture Funds25.5.2022 16:00:00 EEST | Press release

Upflex—the premier global provider of hybrid workspace solutions—announced the closing of its $30 million Series A round. The raise was led by WeWork with participation from notable strategic investors Newmark and Cushman & Wakefield as well as returning investor Ecosystem Integrity Fund, and top venture funds including GPO Fund, Coelius Capital, Industry Ventures, Inertia Ventures, Perennial Private Investments, and Silicon Valley Bank. This brings Upflex’s total funds raised to-date to $34.1 million. Upflex entered into a strategic and exclusive partnership with WeWork in February 2022 which increased Upflex’s global network to over 6,000 bookable locations. As the sole aggregator of WeWork inventory, Upflex and WeWork clients now benefit from enhanced optionality in workspaces as they aim to adopt hybrid work strategies. “We’re excited and humbled to partner with global leaders in commercial real estate and top proptech investors who bring the market expertise and the financial back

Q4 Inc. and Diligent Partner to Deliver Best-In-Class Board Governance and Investor Relations Solutions to Pre-IPO and Public Companies25.5.2022 16:00:00 EEST | Press release

Q4 Inc. (TSX: QFOR) (“Q4”), a leading capital markets communications platform provider, and Diligent, a global leader in modern governance providing SaaS solutions across governance, risk, compliance and ESG, today announced a partnership that will afford pre-IPO and public companies easy access to best-of-breed IR and board governance solutions, equipping them with the tools needed to achieve success at scale. Through the partnership, listing companies will benefit from Diligent’s Board & Leadership Collaboration solution and Q4’s end-to-end Investor Relations platform in one easily accessible offering, allowing them to quickly implement market-leading solutions to fuel good governance and investor relations pre-IPO and beyond. Diligent’s end-to-end Board & Leadership Collaboration solution empowers and informs governance best practices for publicly traded companies across the fiscal year, from routine filings to preparing for an annual general meeting. Meanwhile, Q4’s Investor Relati

Machinations.io Raises $3.3M in Series A Round Led By Hiro Capital25.5.2022 16:00:00 EEST | Press release

Machinations.io, the only platform to design and predict game economies & systems for premium, free2play, and play2earn games, announced today the closing of a $3.3M Series A round, led by Hiro Capital. Machinations will invest the capital into hiring and developing powerful new features. “The team at Machinations.io has forged a set of tools that will be foundational in the future of game design, both centralised games and Web3,” said Spike Laurie, partner at Hiro Capital. “The ability for any development studio to use Machinations’ platform to create in-game economies in a streamlined browser-based solution is revolutionary. We’re excited to help the Machinations team take their vision to game creators across the globe.” Machinations.io was specifically built to tackle the difficulties of designing game economies. It enables game designers to express game systems and perform large-scale simulations to get millions of gameplay progression data with one click of a button. “We’re humble

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom